Innovative AI-Driven Solutions to Address the Growing Complexity of APIs

The complexity of small molecule active pharmaceutical ingredients (APIs) is rising, bringing longer syntheses that challenge innovators' timely readiness for the Clinic. Longer synthetic pathways make it more difficult for process chemists to achieve the ideals of a good API manufacturing process. They also create more complex raw material and intermediate supply chains. Together, these factors can negatively impact startup times and extend preclinical development timelines.

In this On-demand Webinar, we discuss:

• The award-winning AI and vast data that propel a leading predictive retrosynthesis technology.
• How Lonza Small Molecules tailored its performance to suit the needs of our process chemists in Preclinical Route Design.
• Observations of the impact on synthetic route brevity, on supply chain strategy and, ultimately, on route selection.